Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Trulicity ® (dulaglutide)
How should other medications be administered with Trulicity® (dulaglutide)?
Consider reducing insulin/insulin secretagogue dose when initiating Trulicity (dulaglutide). Dulaglutide may reduce absorption of orally co-administered drugs.
Potential for Dulaglutide to Influence the Pharmacokinetics of Other Drugs
Dulaglutide slows gastric emptying and, as a result, may reduce the extent and rate of absorption of orally coadministered medications.1
In clinical pharmacology studies, treatment with dulaglutide did not affect, to any clinically relevant degree, the absorption of coadministered oral medications that included
No dose adjustment is recommended for any of these evaluated coadministered medications.1
Concomitant Use With an Insulin Secretagogue or With Insulin
To reduce the risk of hypoglycemia when initiating dulaglutide treatment, consider reducing the dosage of concomitantly administered
insulin secretagogues, such as sulfonylureas, or
1. Trulicity [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
Date of Last Review: July 13, 2020